3-Hydroxy-3-phenyl-3--propionsaeure | 95372-23-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-Hydroxy-3-phenyl-3--propionsaeure
• 英文别名: 3-hydroxy-3-phenyl-3-piperidin-2-yl-propionic acid；3-Hydroxy-3-phenyl-3-piperidin-2-ylpropanoic acid
• CAS: 95372-23-9
• 化学式: C₁₄H₁₉NO₃
• 分子量: 249.31
• InChiKey: BNNFUSKQCJAZCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• PHACETOPERANE FOR THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
  申请人：Assistance Publique - Hoptiaux de Paris

  公开号：US20150038533A1

  公开（公告）日：2015-02-05

  The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.

  本发明涉及使用α-苯基（哌啶-2-基）甲醇或其药学上可接受的盐和酯，特别是乙酸盐衍生物，更特别是右旋乙酰哌嗪，治疗注意缺陷多动障碍（ADHD）。本发明还提供了α-苯基（哌啶-2-基）甲醇的（S，S）对映体的合成方法，以及右旋乙酰哌嗪的合成方法。
• Phacetoperane for treating of attention deficit hyperactivity disorder
  申请人：NLS PHARMA AG

  公开号：US10456387B2

  公开（公告）日：2019-10-29

  The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.

  本发明涉及用α-苯基(哌啶-2-基)甲醇或其药学上可接受的盐和酯，特别是醋酸盐衍生物，尤其是右旋乙酰哌烷治疗注意缺陷多动障碍（ADHD）。本发明还提供了一种α-苯基（哌啶-2-基）甲醇(S,S)对映体的合成方法，以及一种右旋乙酰哌烷的合成方法。
• PROCEDE DE SYNTHESE DU PHACETOPERANE
  申请人：NLS Pharma AG

  公开号：EP3153168B1

  公开（公告）日：2020-02-26
• PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
  申请人：NLS PHARMA AG

  公开号：US20180214436A1

  公开（公告）日：2018-08-02

  The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.